Artos at JPM 2026

Kicking Off 2026 at JPM: Building What Life Sciences Actually Needs

As we head into JPM Week, we’re taking a moment to reflect on what has been a defining year for Artos—and to look ahead to the conversations and partnerships that will shape 2026.

2025 has been a strong year for Artos. We’ve seen growing adoption across life sciences teams, deeper engagement from enterprise customers, and—most importantly—clear validation that our technical approach is solving real, long-standing problems in regulatory and scientific documentation. There’s no better place than JPM to carry that momentum forward.

Built for the Reality of Life Sciences

Life sciences data is complex, fragmented, and often messy by nature. Regulatory and scientific teams don’t work from clean, perfectly structured inputs—and software that assumes otherwise rarely survives beyond a pilot.

From day one, Artos was built to work with reality.

Our platform does not rely on prompt engineering, brittle configurations, or months of upfront customization to get value. Instead, we’ve focused on a technical foundation that can:

• Work directly with unstructured and semi-structured source content

• Handle inconsistencies across documents, studies, and programs

• Support repeatable, reliable document creation

This approach has allowed teams to move faster without compromising rigor—and to scale usage without increasing operational overhead. As AI adoption accelerates across life sciences, we believe this distinction matters more than ever.

Trust Earned Through Real-World Use

One of the most rewarding parts of 2025 has been the feedback we’ve received from customers using Artos in production—not just in pilots or proofs of concept.

Across regulatory, clinical, and CMC teams, we’ve heard consistent themes:

• Faster first drafts with the right level of flexibility and control for enterprise users

• Single unified platform that scales across all teams

• Greater confidence in AI as a practical, day-to-day tool—not an experiment

We’re deeply grateful to the teams who’ve partnered with us, challenged us, and helped shape the product through real-world use. Their feedback continues to guide how we build—prioritizing reliability, transparency, and workflows that fit seamlessly into existing processes.

Looking Ahead to JPM and Beyond

JPM Week is about more than meetings on a calendar. It’s a chance to reconnect with the life sciences community, exchange perspectives, and explore how technology can meaningfully support the work ahead.

As we kick off 2026, we’re excited to:

• Build deeper relationships with regulatory and scientific leaders

• Learn from peers across biotech, pharma, and technology

• Continue developing software that meets teams where they are

If you’re attending JPM, we’d love to connect. Here’s to a strong start to 2026—and to building what life sciences actually needs, together.

Connect with our team at JPM - drop us a message at josh@artosai.com or mihikaa.jain@artosai.com.